MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Early stage colon cancer and gatekeeper gene

Back to colon cancer blog Blogs list Cancer blog  


Subscribe To Colon Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Early stage colon cancer and gatekeeper gene




The absence or inactivation of the RUNX3 gatekeeper gene paves the way for the growth and development of colon cancer, Singapore researchers report in the Sept. issue of the journal Cancer Cell Prior studies have shown that RUNX3 plays a role in gastric, breast, lung and bladder cancers.

The inactivation of RUNX3 occurs at a very early stage of colon cancer, as per the Singapore scientists' studies with human tissue samples and animal models.

Because the inactivation of RUNX3 is relatively easy to detect, and it is possible that inactivated RUNX3 can be reactivated, this new research may prove to be a crucial step in the development of an early diagnostic test as well as a therapeutic target for colon cancer.



Early stage colon cancer  and gatekeeper gene

Previous to these new findings, researchers knew that a tumor suppressor gene called APC is disrupted in most cases of human colon cancer. APC disruption activates bete-catenin and TCF4, a protein complex that plays an important role in cancer development. For decades, this has been considered the molecular basis for colon cancer.

These latest findings are the first to show that the activity of beta- catenin/TCF4 also is inhibited by RUNX3.

The Singapore researchers are based at the National University of Singapore's (NUS) Yong Loo Lin School of Medicine and the Institute of Molecular and Cell Biology (IMCB), one of the 14 research institutes under the country's Agency for Science, Technology and Research (A*STAR).

In an earlier research, the same team of scientists reported that RUNX3 is a major tumor suppressor of gastric cancer.

Leading the Singapore team is Yoshiaki Ito, M.D., NUS Yong Loo Lin Professor in Medical Oncology and a principal investigator at IMCB.

In their latest study, supported by A*STAR, Dr. Ito and his team analyzed animal models as well as tissue samples from patients diagnosed with colon cancer, with previous ethical approval obtained from the Institutional Review Board, to examine how RUNX3 is involved in colon cancer.

"My team and I have been working on our research for the past six years, and we are extremely excited about how our research findings can be translated into practical clinical applications to help patients suffering from cancers such as bladder, breast, colon and lung," said Dr. Ito. "We certainly look forward to our continuous teamwork with our clinical colleagues in improving the lives of cancer patients,".

The body commonly has a fail-safe mechanism to get rid of abnormal cells. However, this does not work when RUNX3 is not present. RUNX3 is a gene that acts as a gatekeeper and prevents the uncontrolled growth of cells that may result in malignant tumor. Disruption of the RUNX3 gene can cause colon cancer as well as a number of other types of cancers, including those of the bladder, breast, colon and lung.

Said John Wong, M.D., who is Dean of the Yong Loo Lin School of Medicine and director of Singapore's National University Cancer Institute, "Professor Ito's research offers exciting, fresh hope as it lays the groundwork for a diagnostic kit for early detection of colon cancer as well as a possible therapeutic target."

Lee Eng Hin, M.D., Executive Director of A*STAR's Biomedical Research Council, said, "This is a wonderful example of world-class research being done here. As biomedical research efforts in Singapore begin to reap clinically significant outcomes, the working relationships between our researchers and hospital clinicians must be further strengthened. Not only does the success of Professor Ito's work open new doors to colon cancer therapy, it also serves as a leading example for other researchers to follow."


Posted by: Sue    Source




Did you know?
The absence or inactivation of the RUNX3 gatekeeper gene paves the way for the growth and development of colon cancer, Singapore researchers report in the Sept. issue of the journal Cancer Cell Prior studies have shown that RUNX3 plays a role in gastric, breast, lung and bladder cancers.

Medicineworld.org: Early stage colon cancer and gatekeeper gene

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.